+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Induced Pluripotent Stem Cell (iPSC) - Global Strategic Business Report

  • PDF Icon

    Report

  • 349 Pages
  • April 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 4805485

Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $3.1 Billion by 2030

The global market for Induced Pluripotent Stem Cell ((iPSC) estimated at US$1.9 Billion in the year 2023, is projected to reach a revised size of US$3.1 Billion by 2030, growing at a CAGR of 6% over the analysis period 2023-2030.

Vascular Cells, one of the segments analyzed in the report, is projected to record 6.5% CAGR and reach US$1 Billion by the end of the analysis period. Growth in the Cardiac Cells segment is estimated at 7.1% CAGR for the next 8-year period.

The U.S. Market is Estimated at $876.2 Million, While China is Forecast to Grow at 7.7% CAGR

The Induced Pluripotent Stem Cell ((iPSC) market in the U.S. is estimated at US$876.2 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$116.8 Million by the year 2030 trailing a CAGR of 7.7% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 6.1% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Exciting New Report Features

  • Full access to influencer engagement stats
  • Free access to digital archives & research platform. The proprietary platform is fully enabled to unlock creativity and market knowledge of domain experts worldwide in a cohesive and collaborative manner. The state-of-art tools bring world class market perspectives while protecting participants` privacy and identity. Numbers, statistics and market narrative in the report are based on fully curated insights shared by domain experts and influencers in this space.
  • Opportunity to engage with interactive questionnaires that come with real-time data simulator tools & bespoke report generation capabilities
  • Full client access to peer collaborative and interactive platform for cross-enterprise smart exchange of ideas
  • Complimentary report updates for one year
  • Competitor coverage with global market shares of major players
  • Player market presence analysis (Strong/Active/Niche/Trivial) across multiple geographies
  • Access to curated YouTube video transcripts of domain experts/influencer interviews, podcasts, press statements and event keynotes

What to Expect from the Global Economy in 2024

Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 51 Featured)

  • Lonza Group Ltd.
  • Evotec SE
  • FUJIFILM Holdings Corporation
  • Abcam PLC
  • Horizon Discovery Ltd.
  • Cell Signaling Technology, Inc.
  • Cell Applications, Inc.
  • Invivogen
  • ALSTEM, LLC
  • Censo Biotechnologies Ltd.
  • Creative Bioarray
  • Creative Biolabs
  • Axol Bioscience Ltd.
  • ID Pharma Co., Ltd.
  • BlueRock Therapeutics, LLC

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Stem Cells, Application Areas, and the Different Types: A Prelude
  • Applications of Stem Cells
  • Types of Stem Cells
  • Induced Pluripotent Stem Cell (iPSC): An Introduction
  • Production of iPSCs
  • First & Second Generation Mouse iPSCs
  • Human iPSCs
  • Key Properties of iPSCs
  • Transcription Factors Involved in Generation of iPSCs
  • Noteworthy Research & Application Areas for iPSCs
  • Induced Pluripotent Stem Cell ((iPSC) Market: Growth Prospects and Outlook
  • Drug Development Application to Witness Considerable Growth
  • Technical Breakthroughs, Advances & Clinical Trials to Spur Growth of iPSC Market
  • North America Dominates Global iPSC Market
  • Competition
  • Recent Market Activity
  • Select Innovation/Advancement
  • Induced Pluripotent Stem Cell (iPSC) - Global Key Competitors Percentage Market Share in 2023 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
2. FOCUS ON SELECT PLAYERS
  • Axol Bioscience Ltd. (UK)
  • Cynata Therapeutics Limited (Australia)
  • Evotec SE (Germany)
  • Fate Therapeutics, Inc. (USA)
  • FUJIFILM Cellular Dynamics, Inc. (USA)
  • Ncardia (Belgium)
  • Pluricell Biotech (Brazil)
  • REPROCELL USA, Inc. (USA)
  • Sumitomo Dainippon Pharma Co., Ltd. (Japan)
  • Takara Bio, Inc. (Japan)
  • Thermo Fisher Scientific, Inc. (USA)
  • ViaCyte, Inc. (USA)
3. MARKET TRENDS & DRIVERS
  • Effective Research Programs Hold Key in Roll Out of Advanced iPSC Treatments
  • Induced Pluripotent Stem Cells: A Giant Leap in the Therapeutic Applications
  • Research Trends in Induced Pluripotent Stem Cell Space
  • Concerns Related to Embryonic Stem Cells Shift the Focus onto iPSCs
  • Regenerative Medicine: A Promising Application of iPSCs
  • Induced Pluripotent: A Potential Competitor to hESCs?
  • Global Regenerative Medicine Market Size in US$ Billion for 2019, 2021, 2023 and 2025
  • Pluripotent Stem Cells Hold Significance for Cardiovascular Regenerative Medicine
  • Leading Causes of Mortality for Low-Income and High-Income Countries
  • Growing Importance of iPSCs in Personalized Drug Discovery
  • Persistent Advancements in Genetics Space and Subsequent Growth in Precision Medicine Augur Well for iPSCs Market
  • Global Precision Medicine Market (In US$ Billion) for the Years 2018, 2021 & 2024
  • Increasing Prevalence of Chronic Disorders Supports Growth of iPSCs Market
  • Worldwide Cancer Incidence: Number of New Cancer Cases Diagnosed for 2012, 2018 & 2040
  • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Rising Diabetes Prevalence Presents Opportunity for iPSCs Market: Number of Adults (20-79) with Diabetes (in Millions) by Region for 2017 and 2045
  • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for iPSCs Market
  • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
  • Growth in Number of Genomics Projects Propels Market Growth
  • Genomic Initiatives in Select Countries
  • Launch of Numerous iPSCs-Related Clinical Trials Set to Benefit Market Growth
  • iPSCs-based Clinical Trial for Heart Diseases
  • Induced Pluripotent Stem Cells for Stroke Treatment
  • ‘Off-the-shelf’ Stem Cell Treatment for Cancer Enters Clinical Trial
  • iPSCs for Hematological Disorders
  • Market Benefits from Growing Funding for iPSCs-Related R&D Initiatives
  • Human iPSC Banks: A Review of Emerging Opportunities and Drawbacks
  • Human iPSC Banks Worldwide: An Overview
  • Cell Sources and Reprogramming Methods Used by Select iPSC Banks
  • Innovations, Research Studies & Advancements in iPSCs
  • Key iPSC Research Breakthroughs for Regenerative Medicine
  • Researchers Develop Novel Oncogene-Free and Virus-Free iPSC Production Method
  • Scientists Study Concerns of Genetic Mutations in iPSCs
  • iPSCs Hold Tremendous Potential in Transforming Research Efforts
  • Researchers Highlight Potential Use of iPSCs for Developing Novel Cancer Vaccines
  • Scientists Use Machine Learning to Improve Reliability of iPSC Self-Organization
  • STEMCELL Technologies Unveils mTeSR™ Plus
  • Challenges and Risks Related to Pluripotent Stem Cells
  • A Glance at Issues Related to Reprogramming of Adult Cells to iPSCs
  • A Note on Legal, Social and Ethical Considerations with iPSCs
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Vascular Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 2: World 7-Year Perspective for Vascular Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 3: World Recent Past, Current & Future Analysis for Cardiac Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 4: World 7-Year Perspective for Cardiac Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Neuronal Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 6: World 7-Year Perspective for Neuronal Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Liver Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 8: World 7-Year Perspective for Liver Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 9: World Recent Past, Current & Future Analysis for Immune Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 10: World 7-Year Perspective for Immune Cells by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Other Cell Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 12: World 7-Year Perspective for Other Cell Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Cellular Reprogramming by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 14: World 7-Year Perspective for Cellular Reprogramming by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 15: World Recent Past, Current & Future Analysis for Cell Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 16: World 7-Year Perspective for Cell Culture by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Cell Differentiation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 18: World 7-Year Perspective for Cell Differentiation by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Cell Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 20: World 7-Year Perspective for Cell Analysis by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 21: World Recent Past, Current & Future Analysis for Cellular Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 22: World 7-Year Perspective for Cellular Engineering by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Other Research Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 24: World 7-Year Perspective for Other Research Methods by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Drug Development & Toxicology Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 26: World 7-Year Perspective for Drug Development & Toxicology Testing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 27: World Recent Past, Current & Future Analysis for Academic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 28: World 7-Year Perspective for Academic Research by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Regenerative Medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 30: World 7-Year Perspective for Regenerative Medicine by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 31: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 32: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • Table 33: World Induced Pluripotent Stem Cell (iPSC) Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2030
  • Table 34: World Recent Past, Current & Future Analysis for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • Table 35: World 7-Year Perspective for Induced Pluripotent Stem Cell (iPSC) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
CANADA
JAPAN
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
CHINA
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
EUROPE
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
FRANCE
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
GERMANY
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
ITALY
UNITED KINGDOM
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
REST OF EUROPE
ASIA-PACIFIC
  • Induced Pluripotent Stem Cell (iPSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
REST OF WORLDIV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Lonza Group Ltd.
  • Evotec SE
  • FUJIFILM Holdings Corporation
  • Abcam PLC
  • Horizon Discovery Ltd.
  • Cell Signaling Technology, Inc.
  • Cell Applications, Inc.
  • Invivogen
  • ALSTEM, LLC
  • Censo Biotechnologies Ltd.
  • Creative Bioarray
  • Creative Biolabs
  • Axol Bioscience Ltd.
  • ID Pharma Co., Ltd.
  • BlueRock Therapeutics, LLC